Current treatment lacks efficiency
Only one pharmaceutical treatment is presently approved by FDA and EMA for ischemic stroke: thrombolysis, which aims at dissolving the blood clot. This emergency treatment is being administered to approximately 15% of patients overall, mainly because it must be done within 4 hours and 30 minutes (as approved in EU, 3 hours in USA) of the onset of stroke symptoms, in a specialized neurovascular hospital unit.
Moreover, because this treatment could induce bleedings in some patients, it is subjected to some contraindications. Finally, its efficacy remains limited to an estimated 30% success rate. A meta-analysis from 5 randomised trials has shown that thrombolysis protects only around 13% of the patients treated.
Therefore a major need for a new stroke treatment capable of effectively treating a majority of ischemic stroke patients remains.
Since 2015, mechanical thrombectomy has been recognized in several clinical trials and has demonstrated efficacy based on clinical scores at 90 days. The method is based on the use of a device delivered by endovascular access proximal to the occlusion site to disrupt the clot. Although thrombectomy becomes a gold standard, the amount of patients treated remains limited.
Antiplatelet drugs (which inhibit blood platelets aggregation) proved their efficacy in ischemic diseases like myocardial infarction, but they are not recommended in the first 12 to 24 hours for stroke because they tend to induce bleedings that have catastrophic consequences in the brain.
Our innovative solution
In this context, Acticor Biotech took on the mission to develop an innovative antithrombotic compound which could be used in the first 12 hours before switching to antiplatelet agents. Considering the properties of the target GPVI our goal is to achieve an effective action against the formation and growth of the blood clot responsible for the ischemia, without increasing bleeding risks.